Skip to main content


  • Study protocol
  • Open Access
  • Open Peer Review

Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol

  • 1Email author,
  • 1,
  • 2,
  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 1 and
  • 2
BMC Cardiovascular Disorders201111:2

  • Received: 15 November 2010
  • Accepted: 10 January 2011
  • Published:
Open Peer Review reports



Cardiovascular disease (CVD) is the major cause of death after renal transplantation. Not only conventional CVD risk factors, but also transplant-specific risk factors can influence the development of CVD in kidney transplant recipients.

The main objective of this study will be to determine the incidence of post-transplant CVD after renal transplantation and related factors. A secondary objective will be to examine the ability of standard cardiovascular risk scores (Framingham, Regicor, SCORE, and DORICA) to predict post-transplantation cardiovascular events in renal transplant recipients, and to develop a new score for predicting the risk of CVD after kidney transplantation.


Observational prospective cohort study of all kidney transplant recipients in the A Coruña Hospital (Spain) in the period 1981-2008 (2059 transplants corresponding to 1794 patients).

The variables included will be: donor and recipient characteristics, chronic kidney disease-related risk factors, pre-transplant and post-transplant cardiovascular risk factors, routine biochemistry, and immunosuppressive, antihypertensive and lipid-lowering treatment. The events studied in the follow-up will be: patient and graft survival, acute rejection episodes and cardiovascular events (myocardial infarction, invasive coronary artery therapy, cerebral vascular events, new-onset angina, congestive heart failure, rhythm disturbances and peripheral vascular disease).

Four cardiovascular risk scores were calculated at the time of transplantation: the Framingham score, the European Systematic Coronary Risk Evaluation (SCORE) equation, and the REGICOR (Registre Gironí del COR (Gerona Heart Registry)), and DORICA (Dyslipidemia, Obesity, and Cardiovascular Risk) functions.

The cumulative incidence of cardiovascular events will be analyzed by competing risk survival methods. The clinical relevance of different variables will be calculated using the ARR (Absolute Risk Reduction), RRR (Relative Risk Reduction) and NNT (Number Needed to Treat).

The ability of different cardiovascular risk scores to predict cardiovascular events will be analyzed by using the c index and the area under ROC curves. Based on the competing risks analysis, a nomogram to predict the probability of cardiovascular events after kidney transplantation will be developed.


This study will make it possible to determine the post-transplant incidence of cardiovascular events in a large cohort of renal transplant recipients in Spain, to confirm the relationship between traditional and transplant-specific cardiovascular risk factors and CVD, and to develop a score to predict the risk of CVD in these patients.


  • Cardiovascular Event
  • Renal Transplant Recipient
  • Kidney Transplant Recipient
  • Acute Rejection Episode
  • Kidney Transplant Patient


Cardiovascular disease (CVD) is one of the most common complications after renal transplantation, with a considerably higher incidence than in the general population [1]. Although in recent years some authors have documented a significant reduction in cardiovascular death after kidney transplantation [2], today CVD is still the major known cause of death in kidney transplant patients [3].

In addition to the conventional CVD risk factors (such as obesity, smoking habits, diabetes, hypertension or dyslipidemia), several other factors seem to influence the high incidence of cardiovascular events in renal transplant patients [4, 5]. These include, amongst others, the duration of prior dialysis [68], graft function after transplantation [911], hyperhomocysteinemia [1216], elevated inflammatory markers [1618], proteinuria [1922], acute rejection episodes [23], post-transplant diabetes mellitus [6, 2427], and the toxic effects derived from the use of immunosuppressant medications and other drugs [28, 29].

Therefore, when evaluating patients prior to kidney transplantation, special attention should be given to cardiovascular risk factors. To determine the individual risk of cardiovascular events, risk scores have been established in general populations, such as the Framingham Heart Study score [30, 31], the Regicor (Framingham calibrated to Spain) [32], SCORE [33] or DORICA [34]. However, the validity of these equations in more selected populations, such as those of transplant patients, is not well established. In renal transplant recipients, the Framingham score does not seem to accurately predict the individual cardiovascular risk, leading to an underestimation of the cardiovascular event rates [4, 16]. A recent study has corroborated the poor predictive accuracy of the Framingham score in these patients, indicating the need to consider new predictive models that incorporate both traditional and non-traditional cardiovascular risk factors [35].

Determining the incidence of cardiovascular events after a kidney transplant and the associated risk factors is therefore important in order to inform physicians of the need for CVD screening and prevention as part of the transplant evaluation [36]. Moreover, an accurate estimation of a patient's risk of cardiovascular disease could make it possible to identify people at high risk of suffering a cardiovascular event, and intervene proactively before they develop the disease.

This project was designed with three main objectives: firstly, to determine the incidence of post-transplant cardiovascular events after renal transplantation and related factors; secondly, to examine the ability of established cardiovascular risk scores (Framingham, Regicor, SCORE, and DORICA) to predict post-transplantation cardiovascular events in renal transplant recipients; and finally, to develop and validate a cardiovascular risk score to predict the risk of developing a cardiovascular event after kidney transplantation.


Design and study population

Observational, retrospective and prospective cohort study of all adult (> 18 years) patients who underwent primary or repeated kidney transplantation with a graft from a cadaveric or living donor in the A Coruña Hospital (northwest Spain) between 1 January 1981 and 31 December 2008. Patients who had undergone simultaneous kidney-pancreas transplantation will be excluded from the analysis.


All the variables that will be recorded for each one of the patients included in the study are summarized in Additional file 1: Table S1.

Characteristics recorded at the time of transplantation include donor and recipient age and gender, body weight, height, body mass index (weight in kilograms divided by the height in meters squared), primary cause of renal failure (type I diabetes mellitus, type II diabetes mellitus, primary glomerulonephritis, nephrosclerosis including hypertension and renovascular disease, polycystic kidney disease, systemic lupus erythematosus, and others), cold ischemia time, type of dialysis prior to transplant (hemodialysis or peritoneal dialysis), total duration of renal replacement therapy before transplantation, and previous transplants. The date of transplantation and the type of donor (a deceased or living donor) will also be recorded.

Information about other traditional cardiovascular risk factors at the time of transplantation will also be collected, including history of tobacco smoking, hypertension, hypercholesterolemia, left ventricular hypertrophy, prior diabetes and a history of cerebrovascular disease (transient ischemic attacks and strokes), peripheral vascular disease (revascularization procedures and amputations) and malignancies prior to transplantation.

After transplantation, episodes of acute rejection and infections will be registered, together with the patient's smoking status, new-onset diabetes and diagnosis of left ventricle hypertrophy. Biochemical parameters will be collected during the post-transplantation follow-up at week 1, week 2, month 1, month 3, month 6, and yearly thereafter. These will include white blood counts, hematocrit, haemoglobin, cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, creatinine levels and 24-hour proteinuria. At the same time intervals, systolic and diastolic blood pressure will be recorded. Renal function will be estimated using the Cockcroft-Gault formula [37] and the modified Modification of Diet in Renal Disease (MDRD) equation [38]. In the analysis of factors predicting new post-transplant cardiovascular events, the average of laboratory and blood pressure values recorded before the event will be considered.

For the analysis, the cut-points defining the control of each risk factor will be taken from the European Guidelines on CVD prevention [39]. For estimates of dyslipidemia control based on LDL, HDL cholesterol and triglycerides, we will use the cut-points agreed in the consensus statement from the American Diabetes Association and the American College of Cardiology Foundation [40].

The initial immunosuppressive regimen of the patients and changes in treatment during follow-up will be recorded. Dosage of immunosuppressive drugs will also be registered after transplantation at week 1, week 2, months 1, 3 and 6, and yearly thereafter. The use of antihypertensive and lipid-lowering drugs after transplantation will also be registered at the same times.

Post-transplant cardiovascular events are defined as the presence of myocardial infarction, invasive coronary artery therapy, cerebral vascular events (stroke and transient ischemic attacks), new-onset angina, congestive heart failure, rhythm disturbances (ventricular tachycardia, atrial fibrillation and the need for a pacemaker), and peripheral vascular disease. Peripheral vascular disease is defined as the need for invasive therapy or conservatively managed limb gangrene.

Patients will be followed-up from the date of renal transplantation until death or their return to dialysis.

Quantification of cardiovascular risk

Four established cardiovascular risk scores will be applied to the kidney transplant recipients at the time of transplantation: the Framingham risk factor score, the European Systematic Coronary Risk Evaluation (SCORE) equation, and two coronary risk equations that use the calibrated Framingham functions for the Spanish population, the REGICOR (Registre Gironí del COR (Gerona Heart Registry)) and DORICA (Dyslipidemia, Obesity, and Cardiovascular Risk) functions.

The Framingham risk score will be calculated using both the classic Framingham-Anderson equation [30] and the equation modified by Wilson [31]. These scores predict the risk of developing fatal or non-fatal coronary heart disease (CHD) within a 10-year time period in adults between the ages of 30-74 with no known previous history of CHD, stroke, or peripheral vascular disease. CHD includes angina pectoris, myocardial infarction, coronary insufficiency (unstable angina) and coronary heart death.

The original Framingham-Anderson equation includes the following risk factors: age, sex, systolic blood pressure, total cholesterol, HDL-cholesterol, diabetic status, tobacco smoking status and evidence of left ventricular hypertrophy on resting electrocardiogram (ECG). The Framingham-Wilson equation replaces the continuous measurements of systolic blood pressure, total cholesterol and HDL-cholesterol with categorical variables based on the risk categories of the Joint National Committee on Blood Pressure and the National Cholesterol Education Program (NCEP) [4143]. It also takes into account information regarding diastolic and LDL-cholesterol levels, and does not include the diagnosis of left ventricular hypertrophy due to its high association with hypertension and the absence of standard, universally accepted ECG criteria.

The European SCORE was developed by the European Society of Cardiology in 2003 as an estimation of 10-year risk of fatal cardiovascular disease (CVD) in subjects between the ages of 24 and 80. The variables used to calculate this score include age, gender, total cholesterol, systolic blood pressure and current smoking status [33]. The main difference between the SCORE risk chart and the Framingham model is that it estimates the risk for all atherothrombotic cardiovascular manifestations, including stroke, heart failure, peripheral arterial insufficiency or certain aneurysms, and not just CHD. The SCORE charts are currently the CVD charts recommended by the European Societies [44] and the Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention (CEIPC) [45]. The SCORE risk charts calibrated for Spain will be used [46].

Finally, the REGICOR [32] and the DORICA [34] charts are adaptations of the Framingham equation to the Spanish population characteristics. Like the Framingham equation, these functions estimate the risk of coronary mortality and morbidity using information about age, gender, total cholesterol, HDL-cholesterol, systolic and diastolic blood pressure and smoking habits, differentiating diabetic from non-diabetic patients.

Patients will be classified as high-risk patients when their ten-year risk of coronary heart disease is ≥20% according to Framingham [31], REGICOR [32] and DORICA [34] equations or when their ten-year risk of cardiovascular mortality is ≥5% according to the SCORE system [44].

Sample size

During the study period (1981-2008) n = 2059 kidney transplants were performed in the A Coruña Hospital, corresponding to 1794 patients.

This sample size will make it possible to detect as significant, in a Cox regression model, a relative risk of 1.33 or more associated with a prevalence of exposure to a cardiovascular risk factor of 50% and a censored data percentage of 78% (Security: 95%; Statistical power: 80%). Assuming an exposure prevalence of 50% maximizes the sample size necessary to detect a relative risk of this magnitude. According to previously published data for this cohort of patients, the estimated incidence of CVD at five years is 22.2% [47], and so the censoring value was estimated at 78%. In this situation, the sample size required to estimate a relative risk of 1.33 or more (α = 0.05, β = 0.2) would be n = 1755 patients.

Statistical analysis

A descriptive analysis of the variables recorded will be performed. Observed frequencies and percentages will be used for qualitative variables, with their 95% confidence interval, and the mean and standard deviation or median and interquartilic range for quantitative variables.

The primary outcome for this study will be the estimation of the probability of cardiovascular disease in the presence of other competitive events in renal transplant patients. The cumulative incidence of cardiovascular events after kidney transplantation will be analyzed by competing risk survival methods, where each subject is at risk of failure from different causes. Therefore, each patient will be classified in four states of interest (alive with functioning graft, death, graft failure and cardiovascular disease).

Cumulative incidence functions will be used to compare the observed incidence of events between groups [48]. The cumulative incidence function regression model of Fine and Gray will be used for multiple regression analyses [49]. Additionally, the clinical relevance of different variables will be evaluated using the ARR (Absolute Risk Reduction), RRR (Relative Risk Reduction) and NNT (Number Needed to Treat).

In order to analyze the ability of each of the four cardiovascular risk scores to predict cardiovascular events rates, the concordance c index [50] and the area under the receiver-operating characteristic (ROC) curves, using a time-dependent approach [51], will be calculated. To calibrate the scores, relative risk ratios for observed-to-predicted event rates will be computed, and the Hosmer-Lemeshow test will be applied.

Based on the competing risks analysis, a nomogram to estimate the probability of cardiovascular events after kidney transplantation will be developed. The objective is to use the conditional cumulative incidence function to provide a patient-specific prediction of the probability of failure in the setting of competing risks.

The predictive performance of the nomogram will be evaluated by assessing both discrimination and calibration values [52]. A bootstrap re-sampling approach with 1000 replications will be used to reduce overfit bias. Discrimination will be quantified with the concordance c index and the area under the receiving operating characteristic (ROC) curve [50, 51]. The nomogram will then be calibrated graphically, comparing the predicted probabilities with the actual rate of patients with cardiovascular events. A Loess curve will be fitted to the data and compared with an ideal fit. In addition, the Brier score will be calculated as a measure of the predictive accuracy of the model.

A p-value of < 0.05 will be considered as statistically significant (two-sided). Statistical analyses will be carried out with SPSS version 17.0 (SPSS Inc., Chicago, IL.) and R version 2.9.1 (The R Foundation for Statistical Computing), adding the ROCR, Design and Hmisc libraries.


The study has received written approval from the regional Ethics Committee for Clinical Research (CEIC Galicia) (code 2007/019). Informed consent will be obtained from all the participants in the study.


In recent years, several important changes have occurred in the management of kidney transplant patients that have been associated with an improvement in rejection rates and early graft survival [53]. Therefore, attention is now focusing on improving long-term transplant outcomes [3]. Renal dysfunction and increased cardiovascular risk are some of the factors that have a negative impact on long-term graft and patient survival. Although some authors have documented a reduction in CVD-related deaths in kidney transplant recipients in recent years, CVD is still the leading cause of death in patients with a functioning allograft [2].

Several studies have analyzed the risk factors connected with the incidence of cardiovascular events after kidney transplantation [429]. However, the role of some novel risk factors remains unclear. Furthermore, most of the previous studies are based on retrospective analyses of registry data, which contains information only on baseline data at the time of transplantation and the immediate post-transplantation follow-up. As a result, long-term follow-up data on clinical, biochemical and treatment covariates after transplantation is not always available.

This study will allow us to determine the post-transplant incidence of cardiovascular events in a cohort of renal transplant recipients in Spain, as well as to confirm the relationship between some CVD risk factors and the occurrence of a cardiovascular event in these patients. The development of a specific CVD risk score for kidney transplant recipients would make it possible to identify patients at high risk for coronary events at the time of transplantation, or shortly after the transplant. Therefore, this risk assessment could be used to recommend lifestyle changes for patients, to initiate appropriate treatment, or to redesign the immunosuppressive regimens for the prevention of primary or recurrent cardiovascular events in kidney transplant patients. The majority of studies use survival analysis strategies with the methodology of Kaplan and Meier. As this methodology may lead to overestimating the likelihood of the occurrence of the events of interest, we propose a competitive risk analysis in order to study the prognosis of these patients [48, 49].

One of the limitations of this study is that information will mostly be taken retrospectively from hospital records, which could lead to information bias. On the other hand, transplant recipients are subjected to a more exhaustive follow-up than normal, not only during the immediate post-transplant period, but also during the years after the transplant. This fact would minimize any possible information bias. Likewise, during the study period standard immunosuppressive therapy has changed, and the treatment for each patient will depend on the date of transplantation and other medical subjective criteria. In order to control the changes that have occurred over the years, adjustments will be made based on the year of transplantation. Also, the therapeutic changes that occurred during the follow-up period for each of the patients will make it difficult to establish relationships between the medication and the cardiovascular events. Therefore, the impact of immunosuppressant medication on the presence of cardiovascular events in the follow-up could not be well established. The role of immunosuppressant agents must be investigated in greater detail with randomized clinical studies, and not with observational studies of this kind. However, our study will include a large cohort of patients with a long follow-up period, and the sample size is expected to be large enough both to identify individual CVD risk factors from multivariate analysis and to develop a new CVD prediction model.



This research has received a grant from the Spanish Ministry of Science and Innovation, Carlos III Institute, Health Research Fund, no. PI070986, and from the Regional Ministry of Health (Xunta de Galicia, Spain), no. PS09/26.

This study has also received the backing of the Health Promotion and Preventive Activities - Primary Health Care Network, which is supported by grants from the Spanish Ministry of Health ISCIII-RETCI G03/170 and RD06/0018.

The authors would like to thank the nephrologists and urologists who are participating in the follow-up of the patients.

Authors’ Affiliations

Clinical Epidemiology and Biostatistics Unit, A Coruña Hospital, Hotel de Pacientes 7ª Planta, As Xubias 84, A Coruña, 15006, Spain
Department of Nephrology, A Coruña Hospital, As Xubias 84, A Coruña, 15006, Spain


  1. Foley R, Parfrey P, Sarnak M: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998, 9 (12 Suppl): S16-23.PubMedGoogle Scholar
  2. Pilmore H, Dent H, Chang S, McDonald S, Chadban S: Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010, 89 (7): 851-857. 10.1097/TP.0b013e3181caeead.View ArticlePubMedGoogle Scholar
  3. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2009, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney DiseasesGoogle Scholar
  4. Kasiske B, Chakkera H, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000, 11 (9): 1735-1743.PubMedGoogle Scholar
  5. Ojo A: Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006, 82 (5): 603-611. 10.1097/ ArticlePubMedGoogle Scholar
  6. Vanrenterghem Y, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, Ponticelli C: Risk factors for cardiovascular events after successful renal transplantation. Transplantation. 2008, 85 (2): 209-216. 10.1097/TP.0b013e318160254f.View ArticlePubMedGoogle Scholar
  7. Cosio F, Alamir A, Yim S, Pesavento T, Falkenhain M, Henry M, Elkhammas E, Davies E, Bumgardner G, Ferguson R: Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int. 1998, 53 (3): 767-772. 10.1046/j.1523-1755.1998.00787.x.View ArticlePubMedGoogle Scholar
  8. Aalten J, Hoogeveen E, Roodnat J, Weimar W, Borm G, de Fijter J, Hoitsma A: Associations between pre-kidney-transplant risk factors and post-transplant cardiovascular events and death. Transpl Int. 2008, 21 (10): 985-991. 10.1111/j.1432-2277.2008.00717.x.View ArticlePubMedGoogle Scholar
  9. Fellström B, Jardine A, Soveri I, Cole E, Grönhagen-Riska C, Neumayer H, Maes B, Gimpelewicz C, Holdaas H: Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation. 2005, 79 (9): 1160-1163.View ArticlePubMedGoogle Scholar
  10. Forsythe J: Graft function and other risk factors as predictors of cardiovascular disease outcome. Transplantation. 2001, 72 (6 Suppl): S16-19.View ArticlePubMedGoogle Scholar
  11. Meier-Kriesche H, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003, 75 (8): 1291-1295. 10.1097/01.TP.0000061602.03327.E2.View ArticlePubMedGoogle Scholar
  12. Massy Z, Chadefaux-Vekemans B, Chevalier A, Bader C, Drüeke T, Legendre C, Lacour B, Kamoun P, Kreis H: Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant. 1994, 9 (8): 1103-1108.PubMedGoogle Scholar
  13. Friedman A, Rosenberg I, Selhub J, Levey A, Bostom A: Hyperhomocysteinemia in renal transplant recipients. Am J Transplant. 2002, 2 (4): 308-313. 10.1034/j.1600-6143.2002.20404.x.View ArticlePubMedGoogle Scholar
  14. Ducloux D, Motte G, Massy Z: Hyperhomocyst(e)inemia as a risk factor after renal transplantation. Ann Transplant. 2001, 6 (4): 40-42.PubMedGoogle Scholar
  15. Bertoni E, Marcucci R, Zanazzi M, Rosati A, Brunelli T, Fedi S, Pepe G, Di Maria L, Colonna F, Lombardi A, et al: Hyperhomocysteinemia in renal transplant patients: an independent factor of cardiovascular disease. J Nephrol. 2001, 14 (1): 36-42.PubMedGoogle Scholar
  16. Ducloux D, Kazory A, Chalopin J: Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. 2004, 66 (1): 441-447. 10.1111/j.1523-1755.2004.00751.x.View ArticlePubMedGoogle Scholar
  17. Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey D, Sinnott P, Raftery M, Yaqoob M: Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis. 2004, 43 (3): 502-507. 10.1053/j.ajkd.2003.11.011.View ArticlePubMedGoogle Scholar
  18. Bakri R, Afzali B, Covic A, Sriskantharan R, Bharma-Ariza P, Park W, Sriharan M, Dalton N, Wierzbicki A, Crook M, et al: Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant. 2004, 18 (2): 201-204. 10.1111/j.1399-0012.2004.00156.x.View ArticlePubMedGoogle Scholar
  19. Fernández-Fresnedo G, Escallada R, Rodrigo E, Piñera C, de Francisco A, Cotorruelo J, Sanz de Castro S, Arias M: Proteinuria is an independent risk factor of cardiovascular disease in renal transplant patient. Transplant Proc. 2002, 34 (1): 367-View ArticlePubMedGoogle Scholar
  20. Fernández-Fresnedo G, Plaza J, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M: Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant. 2004, 19 (Suppl 3): iii47-51.PubMedGoogle Scholar
  21. Roodnat J, Mulder P, Rischen-Vos J, van Riemsdijk I, van Gelder T, Zietse R, IJzermans J, Weimar W: Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation. 2001, 72 (3): 438-444. 10.1097/00007890-200108150-00014.View ArticlePubMedGoogle Scholar
  22. Alonso A, Oliver J: Causes of death and mortality risk factors. Nephrol Dial Transplant. 2004, 19 (Suppl 3): iii8-10. 10.1093/ndt/gfh1007.PubMedGoogle Scholar
  23. de Mattos A, Prather J, Olyaei A, Shibagaki Y, Keith D, Mori M, Norman D, Becker T: Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006, 70 (4): 757-764. 10.1038/ ArticlePubMedGoogle Scholar
  24. Aakhus S, Dahl K, Widerøe T: Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 1999, 14 (3): 648-654. 10.1093/ndt/14.3.648.View ArticlePubMedGoogle Scholar
  25. Kasiske B, Snyder J, Gilbertson D, Matas A: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003, 3 (2): 178-185. 10.1034/j.1600-6143.2003.00010.x.View ArticlePubMedGoogle Scholar
  26. Chuang P, Gibney E, Chan L, Ho P, Parikh C: Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. Transplant Proc. 2004, 36 (5): 1387-1391. 10.1016/j.transproceed.2004.05.006.View ArticlePubMedGoogle Scholar
  27. Fernández-Fresnedo G, Escallada R, de Francisco A, Rodrigo E, Zubimendi J, Ruiz J, Piñera C, Herraez I, Arias M: Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc. 2003, 35 (2): 700-View ArticlePubMedGoogle Scholar
  28. Miller L: Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002, 2 (9): 807-818. 10.1034/j.1600-6143.2002.20902.x.View ArticlePubMedGoogle Scholar
  29. Arnol M, de Mattos A, Chung J, Prather J, Mittalhenkle A, Norman D: Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation. 2008, 86 (12): 1844-1848. 10.1097/TP.0b013e31818ffec0.View ArticlePubMedGoogle Scholar
  30. Anderson K, Wilson P, Odell P, Kannel W: An updated coronary risk profile. A statement for health professionals. Circulation. 1991, 83 (1): 356-362.View ArticlePubMedGoogle Scholar
  31. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W: Prediction of coronary heart disease using risk factor categories. Circulation. 1998, 97 (18): 1837-1847.View ArticlePubMedGoogle Scholar
  32. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordón F, Ramos R, Sala J, Masià R, Rohlfs I, et al: [Coronary risk estimation in Spain using a calibrated Framingham function]. Rev Esp Cardiol. 2003, 56 (3): 253-261. 10.1157/13043951.View ArticlePubMedGoogle Scholar
  33. Conroy R, Pyörälä K, Fitzgerald A, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, et al: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003, 24 (11): 987-1003. 10.1016/S0195-668X(03)00114-3.View ArticlePubMedGoogle Scholar
  34. Aranceta J, Pérez Rodrigo C, Foz Sala M, Mantilla T, Serra Majem L, Moreno B, Monereo S, Millán J: [Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study]. Med Clin (Barc). 2004, 123 (18): 686-691. 10.1157/13068847.View ArticleGoogle Scholar
  35. Kiberd B, Panek R: Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008, 3 (3): 822-828. 10.2215/CJN.00030108.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Kasiske B, Maclean J, Snyder J: Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006, 17 (3): 900-907. 10.1681/ASN.2005090984.View ArticlePubMedGoogle Scholar
  37. Cockcroft D, Gault M: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16 (1): 31-41. 10.1159/000180580.View ArticlePubMedGoogle Scholar
  38. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130 (6): 461-470.View ArticlePubMedGoogle Scholar
  39. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007, 14 (Suppl 2): S1-113. 10.1097/01.hjr.0000277983.23934.c9.View ArticlePubMedGoogle Scholar
  40. Brunzell J, Davidson M, Furberg C, Goldberg R, Howard B, Stein J, Witztum J, Association AD, Foundation ACoC: Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008, 31 (4): 811-822. 10.2337/dc08-9018.View ArticlePubMedGoogle Scholar
  41. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994, 89 (3): 1333-1445.Google Scholar
  42. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993, 269 (23): 3015-3023. 10.1001/jama.269.23.3015.Google Scholar
  43. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993, 153 (2): 154-183. 10.1001/archinte.153.2.154.Google Scholar
  44. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003, 24 (17): 1601-1610. 10.1016/S0195-668X(03)00347-6.View ArticlePubMedGoogle Scholar
  45. Lobos J, Royo-Bordonada M, Brotons C, Alvarez-Sala L, Armario P, Maiques A, Mauricio D, Sans S, Villar F, Lizcano A, et al: [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: CEIPC 2008 Spanish adaptation]. Rev Esp Salud Publica. 2008, 82 (6): 581-616. 10.1590/S1135-57272008000600002.View ArticlePubMedGoogle Scholar
  46. Sans S, Fitzgerald A, Royo D, Conroy R, Graham I: [Calibrating the SCORE cardiovascular risk chart for use in Spain]. Rev Esp Cardiol. 2007, 60 (5): 476-485. 10.1016/S1885-5857(07)60188-1.View ArticlePubMedGoogle Scholar
  47. Valdés-Cañedo F, Pita-Fernández S, Seijo-Bestilleiro R, Pértega-Díaz S, Alonso-Hernández A, Cillero-Rego S, Fernández-Rivera C, Oliver-García J: Incidence of cardiovascular events in renal transplant recipients and clinical relevance of modifiable variables. Transplant Proc. 2007, 39 (7): 2239-2241.View ArticlePubMedGoogle Scholar
  48. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics. 1988, 16 (3): 1141-1154. 10.1214/aos/1176350951.View ArticleGoogle Scholar
  49. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. JASA. 1999, 94: 496-509.View ArticleGoogle Scholar
  50. Harrell FJ, Califf R, Pryor D, Lee K, Rosati R: Evaluating the yield of medical tests. JAMA. 1982, 247 (18): 2543-2546. 10.1001/jama.247.18.2543.View ArticlePubMedGoogle Scholar
  51. Heagerty P, Lumley T, Pepe M: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000, 56 (2): 337-344. 10.1111/j.0006-341X.2000.00337.x.View ArticlePubMedGoogle Scholar
  52. Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996, 15 (4): 361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
  53. Marcén R, Fernández-Rodriguez A, Rodríguez-Mendiola N, Ponte B, Galeano C, Villafruela J, Teruel J, Burgos F, Ortuño J: Evolution of rejection rates and kidney graft survival: a historical analysis. Transplant Proc. 2009, 41 (6): 2357-2359.View ArticlePubMedGoogle Scholar
  54. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© Pita-Fernández et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.